Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Inclusion Criteria: * Any age (newborn and older) * Ability to comply with the study protocol, in the investigator's judgment * Diagnosis of hemophilia A and current or history of an inhibitor (Bethesda titer ≥0.6 Bethesda units) and currently using bypassing agents (BPAs) for breakthrough bleeds (for PwHA with inhibitors) * Diagnosis of hemophilia A and no history of an inhibitor (Bethesda titer \<0.6 Bethesda units), or a history of an inhibitor that has been tolerized for \>5 years and using FVIII for breakthrough bleeds (for PwHA without inhibitors) * Plan to receive at least 4 loading doses of emicizumab and been adherent to emicizumab prophylaxis by the time of surgery * Undergoing minor surgery within 60 days of study enrollment. Other minor surgical procedures could be included upon consultation and approval of Medical Monitor, but examples include central venous catheter insertion/removal/replacement, simple dental extractions, colonoscopy, cystoscopy, or endoscopy with biopsy, excisional skin biopsy * Must plan to continue emicizumab prophylaxis for at least 1 month after surgery * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \<1% per year during the study period Exclusion Criteria: * Diagnosis of a bleeding disorder other than hemophilia A * Participants who have been tolerized to Factor VIII products (for PwHA with inhibitors) * Tolerized …